The trial is scheduled to take place by the end of the current [Iranian calendar] year (March 20) with 210 volunteers, Mohammad Hossein Fallah, spokesman for the Razi Vaccine and Serum Research Institute, said.

The third phase of the human test has been completed successfully being administered to 23,000 volunteers, Fallah said, adding, so far, no serious side effects have been reported after injecting the first dose and using the inhaled dose of the vaccine.

Booster dose studies are also completed. Recently, the vaccine has obtained the permit to be injected as a booster dose for all vaccines available in the country.

According to these studies, Cov Pars, as a booster dose, can increase the antibody 16 times among those who have received various vaccines such as Sinopharm, Barkat, AstraZeneca, and Sputnik.

Developed by the Razi Vaccine and Serum Research Institute, Razi Cov Pars is the second Iranian-made vaccine that started the clinical trial on February 27, 2021.

The vaccine is protein-based, which employs recombinant versions of the spike protein and tutors the immune system against the virus by producing antibodies.

It is developed in 3 doses. The first two doses are injectable and the third dose is intranasal. The second dose of the vaccine will be injected into the volunteers 21 days later and the third dose will be inhaled 51 days later.

At the end of the second phase of clinical trials, Cov Pars proved 80 percent of the immunogenicity.

Razi Institute (affiliated with the Ministry of Agriculture) is capable of producing 20 million doses of vaccine by the end of 2021, Agriculture Minister Javad Sadatinejad said.

A number of countries have requested to purchase the Cov Pars vaccine for COVID-19, and negotiations are underway to take the necessary measures for export, Fallah said in December 2021.

Domestically-made vaccines

Health Minister Bahram Einollahi has said five coronavirus vaccines have been so far produced domestically.

Made by researchers at the Headquarters for Executing the Order of the Imam, COVIRAN BARKAT was unveiled on December 29, 2020, and received the license for public use on June 14.

It proved effective against Indian strain, according to Hojjat Niki-Maleki, head of the information center of Headquarters for Executing the Order of the Imam.

Moreover, the Iranian-Australian Spikogen vaccine and Pastu Covac, developed jointly by the Pasteur Institute of Iran and Cuba’s Finlay Vaccine Institute, are other vaccines, which have received the emergency use license.

Iran is one of the few countries that has all vaccine production platforms, Mohammad Reza Shanehsaz, former head of the Food and Drug Administration, said in June 2021.

Meanwhile, World Health Organization (WHO) representative to Iran Jaffar Hussain said in September 2021 that the Organization was collecting the necessary information for the registration and certification of Iranian-made coronavirus vaccines.

The post Cov Pars begins clinical trial on adolescents appeared first on Iran News Daily.

Developed by the Razi Vaccine and Serum Research Institute, Razi Cov Pars is the second Iranian-made vaccine that started the clinical trial on February 27.

The vaccine is protein-based, which employs recombinant versions of the spike protein and tutors the immune system against the virus by producing antibodies.

It is developed in 3 doses. The first two doses are injectable and the third dose is intranasal. The second dose of the vaccine will be injected into the volunteers 21 days later and the third dose will be inhaled 51 days later.

The results of the research show that people who received COV Pars did not have any side effects, he stated, adding, even after the shot, none of those who were infected with the virus were hospitalized.

In the second phase of the study, we examined the immunogenicity very closely, and the evidence suggests that the COV Pars vaccine can not only induce antibodies but can also activate cellular immunity, he noted.

In the first to third phases of the trial, 14,000 people received the shot that was completely resistant to the Wuhan variant, but with the advent of the delta strain, the effectiveness of the vaccine was slightly reduced and 20 percent of those who received the vaccine had mild symptoms of the disease, which disappeared within one to two days.

Fortunately, we did not have any cases of death or hospitalization among these people, and this is a sign of the effectiveness on the delta strain, he added.

According to Es’haqi, the third dose of COV Pars complements other vaccines. Pregnant women and people under the age of 18 can also receive the vaccine.

According to the Food and Drug Administration, 14 vaccines are being domestically developed in the country which are in different study phases.

The post Nasal dose of COV Pars reduces virus transmission by 90% appeared first on Iran News Daily.

Developed by the Razi Vaccine and Serum Research Institute, Razi Cov Pars is the second Iranian-made vaccine that started the clinical trial on February 27.

The vaccine is protein-based, which employs recombinant versions of the spike protein and tutors the immune system against the virus by producing antibodies.

It is developed in 3 doses. The first two doses are injectable and the third dose is intranasal. The second dose of the vaccine will be injected into the volunteers 21 days later and the third dose will be inhaled 51 days later.

The first phase of the studies was performed on 133 people, the second phase also started on May 28 by being injected into 500 people.

At the end of the second phase, Cov Pars proved 80 percent of the immunogenicity.

Razi Institute (affiliated to the Ministry of Agriculture) is capable of producing 20 million doses of vaccine by the end of 2021, Agriculture Minister Javad Sadatinejad said.

Ali Es’haqi, head of the Razi Institute, explained that in the third phase, two programs are envisaged.

In the first plan, the vaccine is compared with a consumer vaccine in the country, which inoculates more than 40,000 volunteers. While, through the second plan, the vaccine will be evaluated as the first and second phases with adjuvant or placebo vaccine, and if approved, the third phase will proceed with about 28,000 volunteers.

The Food and Drug Administration issues an emergency use permit with 35 percent of the positive results from the third phase, he emphasized.

If an emergency consumption permit is issued in September, we will provide between 20 and 30 million doses of vaccine to the Ministry of Health, Es’haqi stated.

Homegrown vaccines

Made by researchers at the Headquarters for Executing the Order of the Imam, COVIRAN BAREKAT was unveiled on December 29, 2020, and received the license for public use on June 14.

It proved effective against Indian strain, according to Hojjat Niki-Maleki, head of the information center of Headquarters for Executing the Order of the Imam.

Eleven countries from Asia and South America, and a European country have asked for importing COVIRAN vaccine, Hassan Jalili, the vaccine’s production manager, has said in June.

According to the Food and Drug Administration, 14 vaccines are being domestically developed in the country which are in different study phases.

Pastu Covac coronavirus vaccine, developed by Cuba’s Finlay Vaccine Institute and Pasteur Institute of Iran, is another homegrown vaccine, which has received the emergency use license, after COVIRAN.

The post Cov Pars begins third phase of clinical studies appeared first on Iran News Daily.

Razi Cov Pars is the second Iranian-made vaccine that started the clinical trial on February 27.

Developed by the Razi Vaccine and Serum Research Institute, the vaccine is protein-based, which employs recombinant versions of the spike protein and tutors the immune system against the virus by producing antibodies.

The vaccine is developed in 3 doses, the first two doses are injectable and the third dose is intranasal. The second dose of the vaccine will be injected into the volunteers 21 days later and the third dose will be inhaled 51 days later.

The first phase of the vaccine was performed on 133 people, the second phase also started on May 28 by being administrated to 500 people.

By the end of next week, with the completion of the second dose injection to all volunteers, this phase of the clinical trial will come to an end, Fallah Mehrabadi added.

The third phase of the vaccine is expected to begin by mid-August, being administrated to at least 20,000 people, he explained.

The mass production will start with a capacity of 1 million doses per month, he concluded.

Mass vaccination against COVID-19 started on Iranian citizens with the Russian-made Sputnik V vaccine on February 9.

While Iran continues efforts to mass-produce local candidates, over 13 million doses of foreign vaccines have already been imported and others are expected soon.

Iran is also producing vaccines jointly with two countries Russia, and Australia, which may also be released by September.

According to the Food and Drug Administration, 14 vaccines are being domestically developed in the country which are in different study phases.

The post Cov Pars to produce 1m doses of vaccine monthly appeared first on Iran News Daily.

COV-Pars vaccine will be administered to 13 volunteers in the first stage, and then 120 volunteers will receive the vaccine in four groups of 30.

The vaccine is the first injected-inhaled recombinant corona protein which was unveiled last month in Razi Vaccine and Serum Research Institute in Karaj, Iran.

The institute started working on the vaccine in February last year and after the initial stages, it passed the animal test phase in April 2020.

COV-Pars is developed under the leadership of Iran’s Health Ministry and Food and Drug Organization expertise.

COVIRAN BAREKAT, the first coronavirus vaccine made by Iranian researchers of the Headquarters for Executing the Order of the Imam, was unveiled and injected into three volunteers during a ceremony on December 29, 2020.

Immunogenicity tests have been performed on about 35 volunteers so far, and the results show that the vaccine has higher immunogenicity than we expected, Mohammad Reza Salehi, clinical conductor of the Iranian coronavirus vaccine announced.

“Test results show that about 90 percent of people who received the second dose of the vaccine showed evidence of immunity after two weeks,” he added.

Iran started mass vaccination with Russian-made Sputnik V vaccine, with the priority given to medical staff, the elderly, and people with underlying diseases; and is also going to be co-produced by the two countries.

Importing vaccine from COVAX, a global initiative to ensure rapid and equitable access to COVID-19 vaccines, is also on the agenda.

On January 27, Health Minister Saeed Namaki said that there are four different ways to supply the coronavirus vaccine, including direct purchase from a foreign country, procurement from the World Health Organization’s COVAX facility, a joint production with a Cuban company as well as domestic production of the vaccine.

The post Iranian COVID-19 vaccine undergoes clinical test appeared first on Iran News Daily.